Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery and development of first-in-class antiviral therapeutics for the treatment of chronic HBV infections.
Trius Therapeutics is a biopharmaceutical company developing antibacterial drugs for the treatment of serious infections. Trius went public August 2010 (TSRX) and was acquired by Cubist Pharmaceuticals, Inc. for $704 million in July 2013.
Syrrx is the technological leader in the field of structural proteomics. The company uses its proprietary technologies to generate protein structures, which are then used to rapidly discover new drugs. Japan’s Takeda acquired Syrrx for about $270 million February 2005.
Salmedix is focused on the development of clinical-stage drugs for the treatment of leukemias and lymphomas. Cephalon acquired Salmedix for $160 million May 2005.
Reliant Pharmaceuticals is a specialty pharmaceutical company engaged in the acquisition, development and marketing of pharmaceutical products. GlaxoSmithKline acquired Reliant for $1.65 billion November 2007.
Pharmion is an emerging pharmaceutical company focused on marketing drugs that require specialized medical education and marketing programs. The company’s initial focus is on drugs currently marketed for the treatment of cancer and related diseases for markets in the US, as well as in Europe and other major international markets. Celgene aquired Pharmion for $2.9 billion March 2008.
ParAllele BioScience accelerated healthcare breakthroughs by providing comprehensive genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. Affymetrix acquired ParAllele for $120 million in June 2005.
NovaCardia is an emerging cardiovascular pharmaceutical company focused on the development and commercialization of novel clinical stage drug candidates. Merck acquired NovaCardia for $350 million in July 2007.
Jazz Pharmaceuticals develops and markets drugs to the neurology and psychiatry markets. Jazz went public July 2007.
Genomic Health gives cancer patients and physicians insight needed to help make quality treatment decisions. The first diagnostic assay developed by Genomic Health Oncotype DX(TM) is a breast cancer test. Genomic Health went public September 2005.
ForteBio delivers simple, accessible bio-molecule detection and analysis solutions to the life sciences market. Pall Corporation acquired ForteBio for an undisclosed amount in March 2012. Read More
Clovis Oncology is focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis went public November 2011.
Cadence Pharmaceuticals is developing and commercializing pharmaceuticals to meet the needs of hospitalized patients and their caregivers. Cadence went public November 2011 (CADX) and was acquired by Mallinckrodt plc for $1.3 billion in February 2014.
Amira is a discovery and early development company focused on novel drugs to treat inflammatory and fibrotic disease. Bristol-Myers Squibb acquired Amira for up to $475 million July 2011. Read More
Ocular Therapeutix has a novel PEG hydrogel platform technology focused on ocular sealant, wound closure, and drug delivery. Ocular Therapeutix went public in July 2014.
Veracyte is a company focused on molecular diagnostics. Veracyte went public in October 2013.
Quanticel is a pharmaceutical company focused on the development of improved cancer therapeutics and their companion diagnostics.
OpGen is developing a molecular biology system to automate rapid (2-hour) identification of infection-causing bacteria for deployment in the hospital microbiology lab.
Okairos is a clinical stage biopharmaceutical company using a best-in-class, proprietary genetic vaccine technology to develop vaccines for major unmet diseases, such as malaria, hepatitis C (HCV) and a universal influenza vaccine. In May 2013, Okairos was acquired by GSK for $324 million.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. CymaBay went public in August 2014.
Kythera is focused on science and innovation in aesthetic medicine. Kythera went public in October 2012.
Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design’s clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design went public in July 2014 and is listed on NASDAQ under the symbol IMDZ.
Fluidigm has developed the biological and chemical equivalent of the integrated circuit called Integrated Fluidic Circuits (IFC’s). IFC’s incorporate tens of thousands of miniature channels, pumps and valves. Fluidigm completed its IPO in February 2011.
Flexion is developing novel therapeutics for the targeted treatment of musculoskeletal disorders. Flexion went public in February 2014.
FivePrime accelerates drug discovery by rapidly isolating and assaying the world’s largest collection of pharmaceutically relevant targets and therapeutics from the human genome. FivePrime went public in September 2013.
Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders and inflammatory diseases
Alexza is a specialty pharmaceutical company developing fast onset medications. Alexza went public in August 2013.
Achaogen is discovering and developing life-saving antibiotics. Achaogen went public in March 2014.